Table 1 Summary of concomitant therapy rules

Prohibited

Very potent topical corticosteroids (e.g., Dermovate)

Any topical treatment that is likely to impact signs and symptoms of PPP (e.g., corticosteroids, vitamin D analogues, calcineurin inhibitors, retinoids, keratolytics, tar or urea)

Phototherapy or PUVA

Methotrexate, Cyclosporine, Acitretin, Alitretinoin, FAE

Etanercept or Adalimumab

Infliximab or Ustekinumab or Secukinumab

Other TNF antagonists

Other systemic immunosuppressive therapy

Other investigational monoclonal antibody

Other investigational drugs

Allowable topical therapy

Emollients

Topical hydrocortisone, antihistamine for injection – site reactions

Mild topical corticosteroids for the treatment of psoriasis at sites other than hands and feet applied with gloves

‘Rescue’ topical therapy

Potent corticosteroid OD. To be dispensed only by the study team, at the Investigator’s discretion. Amounts prescribed to be recorded.